Imricor Medical Systems (ASX:IMR) said that its Advantage-MR electrophysiology recording and cardiac stimulator system received CE mark certification under the European Union's new medical device regulations regime, according to a Thursday Australian bourse filing.
The commercial launch of its second-generation Vision-MR ablation catheter and the new Advantage-MR system is planned to start in June across new and existing sites in the EU.
In February, the company's second-generation Vision-MR ablation catheter received CE mark approval under the medical device regulations regime.
Imricor's shares fell almost 4% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.